Tag: Biotech and Pharmaceuticals
-
AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
-
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
-
Jim Cramer says this former Covid market darling is finally investable again
CNBC’s Jim Cramer said Moderna’s expanding pipeline in treatments for cancer and other diseases provides a compelling long-term investment thesis.
-
FDA lets Philip Morris market Zyn nicotine pouches as less harmful than cigarettes
The Trump administration has expanded access to nicotine products despite concerns from public health critics about youth use and addiction.
-
Medicare will start covering obesity drugs for the first time. Here’s what patients should know
The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.
-
French biotech stock soars 25% after new data on experimental medicine
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.
-
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned.
-
America can’t get enough of protein. The dairy industry can’t keep up
Demand for whey protein is off the charts as American diet trends change and GLP-1s boom, and the dairy industry is struggling to produce enough.
-
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo.
-
Estrogen patches are hard to find, and it may not be resolved any time soon
Estrogen patches are in short supply as demand for menopause treatments skyrockets, and it could take at least a year for manufacturers to catch up.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
